10-08-2018 09:29 AM CET - Health & Medicine
Print

Synovial Sarcoma - Pipeline Review, H2 2018| Key players : Epizyme , GlaxoSmithKline Plc,Ignyta , Immune Design ,Immunocore

Press release from: HTF Market Intelligence Consulting Pvt. Ltd.
Synovial Sarcoma
Synovial Sarcoma


A new research document is added in HTF MI database of 241 pages, titled as 'Synovial Sarcoma - Pipeline Review, H2 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as CoBioRes NV, Epizyme , GlaxoSmithKline Plc,Ignyta , Immune Design ,Immunocore ,Johnson & Johnson etc The report will help you gain market insights, future trends and growth prospects for forecast period.

Request a sample report @ www.htfmarketreport.com/sample-report/1301536-synovial-sa...

Synovial Sarcoma - Pipeline Review, H2 2018

HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2018, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

HTF’s Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 9, 4 and 9 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Buy this report @ www.htfmarketreport.com/buy-now?format=1&report=1301536

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
CoBioRes NV
Epizyme Inc
GlaxoSmithKline Plc
Ignyta Inc
Immune Design Corp
Immunocore Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Novartis AG
OncoTherapy Science Inc
Pfizer Inc
Takara Bio Inc

Get Customization in the Report, Enquire Now @ www.htfmarketreport.com/enquiry-before-buy/1301536-synovi...

Table of Contents
Table of Contents 2
Introduction 4
Synovial Sarcoma - Overview 5
Synovial Sarcoma - Therapeutics Development 6
Synovial Sarcoma - Therapeutics Assessment 14
Synovial Sarcoma - Companies Involved in Therapeutics Development 24
Synovial Sarcoma - Drug Profiles 32
Synovial Sarcoma - Dormant Projects 220
Synovial Sarcoma - Discontinued Products 221
Synovial Sarcoma - Product Development Milestones 222
Appendix 237List of Tables
Number of Products under Development for Synovial Sarcoma, H2 2018
Number of Products under Development by Companies, H2 2018
Number of

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/1301536-synovial-sarcoma-...

It's vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
www.linkedin.com/company/13388569/
plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author
www.facebook.com/htfmarketintelligence/
twitter.com/htfmarketreport

This release was published on openPR.
News-ID: 1286096 • Views: 260
More releasesMore releases

You can edit or delete your press release here: